Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, Vacca G, Vacchiano V, Nardone A, Triassi M, Morra VB. Moccia M, et al. Among authors: carotenuto a. Clin Chem Lab Med. 2015 Apr;53(5):753-9. doi: 10.1515/cclm-2014-0744. Clin Chem Lab Med. 2015. PMID: 25241733
Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study.
Lanzillo R, Moccia M, Carotenuto A, Vacchiano V, Satelliti B, Panetta V, Brescia Morra V. Lanzillo R, et al. Among authors: carotenuto a. Mult Scler. 2015 Aug;21(9):1215-6. doi: 10.1177/1352458514562989. Epub 2015 Feb 6. Mult Scler. 2015. PMID: 25662354 Clinical Trial. No abstract available.
Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, Postiglione E, De Luca Picione C, Vastola M, Maniscalco GT, Palladino R, Brescia Morra V. Moccia M, et al. Among authors: carotenuto a. J Neurol. 2015;262(4):961-7. doi: 10.1007/s00415-015-7666-y. Epub 2015 Feb 12. J Neurol. 2015. PMID: 25673130
The Framingham cardiovascular risk score in multiple sclerosis.
Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, Massarelli M, Carotenuto A, Postiglione E, Caporale O, Triassi M, Brescia Morra V. Moccia M, et al. Among authors: carotenuto a. Eur J Neurol. 2015 Aug;22(8):1176-83. doi: 10.1111/ene.12720. Epub 2015 Apr 27. Eur J Neurol. 2015. PMID: 25912468
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. Lanzillo R, et al. Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. Mult Scler. 2016. PMID: 26466947 Clinical Trial.
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, Calignano A, Muccioli GG, Orefice G. Orefice NS, et al. Among authors: carotenuto a. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007/s13311-016-0420-z. Neurotherapeutics. 2016. PMID: 26857391 Free PMC article. Clinical Trial.
326 results